β2-agonists and exercise-induced asthma

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 163-180

  Anderson, Sandra D ^a   Caillaud, Corinne ^b   Brannan, John D ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

2 agonists; Exercise induced asthma; Mast cells; Tolerance

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

BRONCHOSPASM; BRONCHUS; CLINICAL TRIAL; DESENSITIZATION; DISEASE SEVERITY; DRUG EFFECT; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAST CELL; PHYSICIAN; PRESCRIPTION; REVIEW; SMOOTH MUSCLE FIBER; DRUG TOLERANCE; PATHOPHYSIOLOGY;

ADRENERGIC BETA-AGONISTS; ASTHMA, EXERCISE-INDUCED; DRUG TOLERANCE; HUMANS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33751318184     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:163     Document Type: Review

References (103)

1. Anderson, S. D. (1997), Exercise-induced asthma, in Allergy & Allergic Diseases, Kay, A. B., ed. Blackwell Scientific Publications, Oxford, pp. 692-711.
2. Sterk, P. J., Fabbri, L. M., Quanjer, P. H., et al. (1993), Airway responsiveness: Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur. Respir. J. 6, 53-83.
3. Task Force on Recognizing and Diagnosing Exercise-Related Asthma, Respiratory and Allergic Diseases in Sport. (2005), Evidence-based recommendations for diagnosis of exercise-induced asthma in athletes. Eur. Respir. Mon. 33, 102-104.
4. Kemp, J. P., Dockhorn, R. J., Shapiro, G. G., et al. (1998), Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J. Pediatr. 133, 424-428.
5. Edelman, J. M., Turpin, J. A., and Bronsky, E. A. (2000), Oral Montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann. Intern. Med. 132, 97-104.
6. Patessio, A., Podda, A., Carone, M., Trombetta, N., and Donner, C.F. (1991), Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. Eur. Respir. J. 4, 296-300.
7. Anderson, S. D., Rodwell, L. T., Du Toit, J., and Young, I. H. (1991), Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 100, 1254-1260.
8. Kemp, J. P., Dockhorn, R. J., Busse, W. W., and Bleecker, E. R. (1994), Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 150, 1612-1615.
9. Anderson, S. D., Lambert, S., Brannan, J. D., et al. (2001), Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Med. Sci. Sports Exerc. 33, 893-900.
10. Anderson, S. D., Sue-Chu, M., Perry, C. P., et al. (2006), Bronchial challenges in athletes applying to inhale a b2-agonist at the 2004 summer Olympics. J. Allergy Clin. Immunol. 117, 767-773.
11. Asthma Management Handbook 2002, National Asthma Council Australia. National Asthma Council Australia Ltd, South Melbourne.
12. Mims Annual 1999, Caswell, A., ed. MediMedia Australia Pty Ltd, Sydney, pp. 2-92.
13. Weiler, J. M., Nathan, R. A., Rupp, N. T., Kalberg, C. J., Emmett, A., and Dorinsky, P. M. (2005), Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann. Allergy Asthma Immunol. 94, 65-72.
14. Inman, M. D. and O'Byrne, P. M. (1996), The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 153, 65-69.
15. Hancox, R. J., Subbarao, P., Kamada, D., Watson, R. M., Hargreave, F. E., and Inman, M. D. (2002), Beta2-agonist tolerance and exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 165, 1068-1070.
16. Dhillon, D. P. (1991), Studies in exercise-induced asthma. Eur. Respir. Rev. 1, 265-267.
17. Ramage, L., Lipworth, B. J., Ingram, C. G., Cree, I. A., and Dhillon, D. P. (1994), Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. 88, 363-368.
18. Nelson, J. A., Strauss, L., Skowronski, M., Ciufo, R., Novak, R., and McFadden, E. R. (1998), Effect of long-term salmeterol treatment on exercise-induced asthma. N. Engl. J. Med. 339, 141-146.
19. Simons, F. E., Gerstner, T. V., and Cheang, M. S. (1997), Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99, 655-659.
20. Storms, W., Chervinsky, P., Ghannam, A. F., Bird, S., Hustad, C. M., and Edelman, J. M. (2004), A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 98, 1051-1062.
21. Evans, D. W., Salome, C. M., King, G. G., Rimmer, S. J., Seale, J. P., and Woolcock, A. J. (1997), Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic nonasthmatic subjects. Thorax 52, 136-142.
22. Bisgaard, H. (2000), Long-acting beta2-agonists in management of childhood asthma: A critical review of the literature. Pediatr. Pulmonol. 29, 221-234.
23. Lipworth, B. J. (1997), Airway subsensitivity with long-acting beta 2-agonists. Is there a cause for concern? Drug-Saf. 16, 295-308.
24. Anderson, S. D. and Brannan, J. D. (2004), Long-acting beta2-adrenoceptor agonists and exercise-induced asthma: Lessons to guide us in the future. Paediatr. Drugs 6, 161-175.
25. Hanania, N. A. and Moore, R. H. (2004), Anti-inflammatory activities of beta2-agonists. Curr. Drug Targets Inflamm. Allergy 3, 271-277.
26. 2 adrenergic receptor function, response and regulation. J. Allergy Clin. Immunol. 117, 18-24.
27. Hayes, M. J., Qing, F., Rhodes, C. G., et al. (1996), In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Am. J. Respir. Crit. Care Med. 154, 1277-1283.
28. Haney, S. and Hancox, R. J. (2005), Rapid onset of tolerance to beta-agonist bronchodilation. Respir. Med. 99, 566-571.
29. Shapiro, G. S., Yegen, U., Xiang, J., Kottakis, J., and Della Cioppa, G. (2002), A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin. Ther. 24, 2077-2087.
30. Grönneröd, T. A., Von Berg, A., Schwabe, G., and Soliman, S. (2000), Formoterol via Turbuhaler® gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir. Med. 94, 661-667.
31. Green, C. P. and Price, J. F. (1992), Prevention of exercise induced asthma by inhaled salmeterol zinofoate. Arch. Dis. Child. 67, 1014-1017.
32. Nielsen, K. G., Skov, M., Klug, B., Ifversen, M., and Bisgaard, H. (1997), Flow dependent effect of formoterol dry-powder inhaled from the Aeroliser®. Eur. Respir. J. 10, 2105-2109.
33. Daugbjerg, P., Nielsen, K. G., Skov, M., and Bisgaard, H. (1996), Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. Acta. Paediatr. 85, 684-687.
34. Bensch, G., Berger, W. E., Blokhin, B. M., et al. (2002), One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann. Allergy Asthma Immunol. 89, 180-190.
35. Anderson, S. D., Bye, P. T. P., Schoeffel, R. E., Seale, J. P., Taylor, K. M., and Ferris, L. (1981), Arterial plasma histamine levels at rest, during and after exercise in patients with asthma: Effects of terbutaline aerosol. Thorax 36, 259-267.
36. Yates, D. H., Kharitonov, S., and Barnes, P. J. (1996), An inhaled glucocorticoid does not prevent tolerance to the protective effect of a long-acting inhaled beta 2-agonist. Am. J. Respir. Crit. Care Med. 154, 1603-1607.
37. Cockcroft, D., Swystun, V. A., and Bhagat, R. (1995), Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med. 152, 1485-1489.
38. Hancox, R. J., Aldridge, E. E., Cowan, J. O., et al. (1999), Tolerance to beta-agonists during acute bronchoconstriction. Eur. Respir. J. 14, 283-287.
39. Jones, S. L., Cowan, J. O., Flannery, E. M., Hancox, R. J., Herbison, G. P., and Taylor, D. R. (2001), Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. 17, 368-373.
40. Booth, H., Bish, R., Walters, J., Whitehead, F., and Walters, E. H. (1996), Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 51, 1100-1104.
41. Henriksen, J. M., Agertoft, L., and Pedersen, S. (1992), Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J. Allergy Clin. Immunol. 89, 1176-1182.
42. Boner, A. L., Spezia, E., Piovesan, P., Chiocca, E., and Maiocchi, G. (1994), Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am. J. Respir. Crit. Care Med. 149, 935-938.
43. Carlsen, K. H., Roksund, O., Olsholt, K., Nija, F., Leegard, J., and Bratten, G. (1995), Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Eur. Respir. J. 8, 1852-1855.
44. de Benedictis, F. M., Tuteri, G., Pazzelli, P., Niccoli, A., Mezzetti, D., and Vaccaro, R. (1996), Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses. Eur. Respir. J. 9, 2099-2103.
45. Wraight, J. M., Hancox, R. J., Herbison, G. P., Cowan, J. O., Flannery, E. M., and Taylor, D. R. (2003), Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur. Respir. J. 21, 810-815.
46. Aldridge, R. E., Hancox, R. J., Robin Taylor, D., et al. (2000), Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 161, 1459-1464.
47. Swystun, V. A., Gordon, J. R., Davis, E. B., Zhand, X., and Cockcroft, D. W. (2000), Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J. Allergy Clin. Immunol. 106, 57-64.
48. Cheung, D., Timmers, M. C., Zwinderman, A. H., Bel, E. H., Dijkman, J. H., and Sterk, P. J. (1992), Long-term effects of a long acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl. J. Med. 328, 665,666.
49. Kalra, S., Swystun, V. A., Bhagat, R., and Cockcroft, D. W. (1996), Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109, 953-956.
50. Lim, S., Jatakanan, A., John, M., et al. (1999), Effect of inhaled budesonide on lung function and airway inflammation. Am. J. Respir. Crit. Care Med. 159, 22-30.
51. Mak, J. C. W., Roffel, F., Katsunuma, T., Elzinga, C. R. S., Zaagsma, J., and Barnes, P. J. (2000), Up-regulation of airway smooth muscle histamine H1 receptor mRNA, protein, and function by beta 2-adrenoceptor activation. Mol. Pharmacol. 57, 857-864.
52. McGraw, D. W., Almoosa, K. F., Paul, R. J., Kobilka, B. K., and Liggett, S. B. (2003), Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J. Clin. Invest. 112, 619-626.
53. McGraw, D. W. and Liggett, S. B. (2005), Molecular mechanisms of beta2-adrenergic receptor function and regulation. Proc. Am. Thorac. Soc. 2, 292-296; discussion 311,312.
54. Liggett, S. B. (2002), Update on current concepts of the molecular basis of beta2-adrenergic receptor signaling. J. Allergy Clin. Immunol. 110, S223-S227.
55. Israel, E., Chinchilli, V. M., Ford, J. G., et al. (2004), Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364, 1505-1512.
56. Wechsler, M. E., Lehman, E., Lazarus, S. C., et al. (2006), {beta}-adrenergic Receptor Polymorphisms and Response to Salmeterol. Am. J. Respir. Crit. Care Med. 173, 519-526.
57. 2-adrenoceptor agonists in human lung mast cells. Brit. J. Pharmacol. 138, 512-520.
58. 2- adrenoceptor-mediated responses by salmeterol and formoterol. Br. J. Pharmac. 141, 163-171.
59. 2-adrenoceptor-mediated responses in mast cells. Br. J. Pharmac. 143, 71-80.
60. Caillaud, C., Le Creff, C., Legros, P., and Denjean, A. (2003), Strenuous exercise increases plasmatic and urinary leukotriene E4 in cyclists. Can. J. Appl. Physiol. 28, 793-806.
61. Mickleborough, T. D., Murray, R. L., Ionescu, A. A., and Lindley, M. R. (2003), Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am. J. Respir. Crit. Care Med. 168, 1181-1189.
62. Anderson, S. D. and Kippelen, P. (2005), Exercise-induced bronchoconstriction: Pathogenesis. Curr. Allergy Asthma Reports 5, 116-122.
63. Holzer, K., Anderson, S. D., Chan, H.-K., and Douglass, J. (2003), Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am. J. Respir. Crit. Care Med. 167, 534-547.
64. Leuppi, J. D., Anderson, S. D., Brannan, J. D., Belousova, E., Reddel, H. K., and Rodwell, L. T. (2005), Questionnaire responses that predict airway response to hypertonic saline. Respiration 72, 52-60.
65. Anderson, S. D., Wong, R., Bennett, M., Beckert, L. (2006) Summary and knowledge and thinking about asthma and diving since 1993. Diving Hyperbar. Med. 36, 12-18.
66. Hofstra, W. B., Neijens, H. J., Duiverman, E. J., et al. (2000), Dose-response over time to inhaled fluticasone propionate: treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr. Pulmonol. 29, 415-423.
67. Jonasson, G., Carlsen, K. H., and Hultquist, C. (2000), Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. Pediatr. Allergy Immunol. 11, 120-125.
68. Pedersen, S. and Hansen, O. R. (1995), Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. 95, 29-33.
69. Anderson, S. D., Rozea, P. J., Dolton, R., and Lindsay, D. A. (1975), Inhaled and oral bronchodilator therapy in exercise-induced asthma. Aust. N.Z. J. Med. 5, 544-550.
70. Anderson, S. D., Seale, J. P., Rozea, P., Bandler, L., Theobald, G., and Lindsay, D. A. (1976), Inhaled and oral salbutamol in exercise-induced asthma. Am. Rev. Respir. Dis. 114, 493-500.
71. Schoeffel, R. E., Anderson, S. D., and Seale, J. P. (1981), The protective effect and duration of action of metaproteronol aerosol on exercise-induced asthma. Ann. Allergy 46, 273-275.
72. Smith, C. M., Anderson, S. D., and Seale, J. P. (1988), The duration of action of the combination of fenoterol hydrobromide and ipratropium bromide in protecting against asthma provoked by hyperpnea. Chest 94, 709-717.
73. Woolley, M., Anderson, S. D., and Quigley, B. (1990), Duration of protective effect of terbutaline sulphate and cromolyn sodium alone and in combination on exercise-induced asthma. Chest 97, 39-45.
74. Drury, D. E., Chong, L. K., Ghahramani, P., and Peachell, P. T. (1998), Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells. Br. J. Pharmacol. 124, 711-718.
75. Brightling, C. E., Bradding, P., Symon, F. A., Holgate, S. T., Wardlaw, A. J., and Pavord, I. D. (2002), Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346, 1699-1705.
76. McFadden, E. R., Lenner, K. A., and Strohl, K. P. (1986), Postexertional airway rewarming and thermally induced asthma. J. Clin. Invest. 78, 18-25.
77. Spooner, C., Spooner, G., and Rowe, B. (2003), Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst. Rev. 4, CD002307.
78. Church, M. K. and Hiroi, J. (1987), Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmac. 90, 421-429.
79. Silverman, M. and Andrea, T. (1972), Time course of effect of disodium cromoglycate on exercise-induced asthma. Arch. Dis. Child. 47, 419-422.
80. Baki, A. and Orhan, F. (2002), The effect of loratadine in exercise-induced asthma. Arch. Dis. Child. 86, 38,39.
81. Patel, K. R. (1984), Terfenadine in exercise-induced asthma. Brit. Med. J. 85, 1496,1497.
82. Shimizu, T., Mochizuki, H., Shigeta, M., and Morikawa, A. (1997), Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am. J. Respir. Crit. Care Med. 155, 170-173.
83. Dahlén, B., Roquet, A., Inman, M. D., et al. (2002), Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 109, 789-793.
84. Peroni, D. G., Piacentini, G. L., Pietrobelli, A., et al. (2002), The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Eur. Respir. J. 19, 104-107.
85. Hallstrand, T. S., Moody, M. W., Wurfel, M. M., Schwartz, L. B., Henderson, W. R., and Aitken, M. L. (2005), Inflammatory basis of exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 172, 679-689.
86. Anderson, S. D. (1985), Exercise-induced asthma. The state of the art. Chest 87S, 191S-195S.
87. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98, 421-432.
88. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52, 1030-1035.
89. Anderson, S. D. (1984), Is there a unifying hypothesis for exercise-induced asthma? J. Allergy Clin. Immunol. 73, 660-665.
90. Anderson, S. D. and Daviskas, E. (2000), The mechanism of exercise-induced asthma is... J. Allergy Clin. Immunol. 106, 453-459.
91. Eggleston, P. A., Kagey-Sobotka, A., Schleimer, R. P., and Lichtenstein, L. M. (1984), Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am. Rev. Respir. Dis. 130, 86-91.
92. Brannan, J. D., Gulliksson, M., Anderson, S. D., Chew, N., and Kumlin, M. (2003), Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur. Respir. J. 22, 491-496.
93. Brannan, J. D., Gulliksson, M., Anderson, S. D., Chew, N., Seale, J. P., and Kumlin, M. (2006), Inhibition of PGD2 release from mast cell protects against mannitol-induced airway narrowing. Eur. Respir. J. 27, 944-950.
94. Waldeck, B. (2002), Beta-adrenoceptor agonists and asthma-100 years of development. Eur. J. Pharmacol. 445, 1-12.
95. Solèr, M., Joos, L., Bolliger, C. T., Elsasser, S., and Perruchoud, A. P. (1994), Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. Eur. Respir. J. 7, 1973-1977.
96. Anderson, S. D., Silverman, M., Konig, P., and Godfrey, S. (1975), Exercise-induced asthma. A Review. Br. J. Dis. Chest 69, 1-39.
97. Tullett, W. M., Tan, K. M., Wall, R. T., and Patel, K. R. (1985), Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma. Thorax 40, 41-44.
98. Patel, K. R. and Wall, R. T. (1986), Dose-duration effect of sodium cromoglycate aerosol in exercise-induced asthma. Eur. J. Respir. Dis. 69, 256-260.
99. Albazzaz, M. K., Neale, M. G., and Patel, K. R. (1992), Dose duration of nebulized nedocromil sodium in exercise-induced asthma. Eur. Respir. J. 5, 967-969.
100. Tsuji, T., Kato, T., Kimata, M., et al. (2004), Differential effects of beta2-adrenoceptor desensitization on the IgE-dependent release of chemical mediators from cultured human mast cells. Biol. Pharm. Bull. 27, 1549-1554.
101. Giannini, D., Carlett, A., Dente, F. L., et al. (1996), Tolerance to the protective effect of salmeterol on allergen challenge. Chest 110, 1452-1457.
102. Food and Drug Administration. (2005), Pulmonary-Allergy Drugs Advisory Committee. Available at: www. fda.gov/ohrms/2005.
103. Nielsen, K. G., Auk, I. L., Bojsen, K., Ifversen, M., Klug, B., and Bisgaard, H. (1998), Clinical effect of Diskus™ dry-powder inhaler at low and high inspiratory flow rates in children. Eur. Respir. J. 11, 350-354.